Evidence map›Paper›PMID 34066779›Full record

ArticleInternational journal of molecular sciences2021

Is LRP2 Involved in Leptin Transport over the Blood-Brain Barrier and Development of Obesity?

Elvira S Sandin, Julica Folberth, Helge Müller-Fielitz, Claus U Pietrzik, Elisabeth Herold, Thomas E Willnow, Paul T Pfluger, Ruben Nogueiras, Vincent Prevot, Thomas Krey and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Elvira S SandinInstitute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lübeck, 23562 Lübeck, Germany.
Julica FolberthInstitute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lübeck, 23562 Lübeck, Germany.
Helge Müller-FielitzInstitute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lübeck, 23562 Lübeck, Germany.ORCID 0000-0003-2815-4426
Claus U PietrzikInstitute for Pathobiochemistry, University Medical Center of Johannes Gutenberg University Mainz, 55099 Mainz, Germany.
Elisabeth HeroldInstitute of Biochemistry, Center of Structural and Cell Biology in Medicine, University of Lübeck, 23562 Lübeck, Germany.
Thomas E WillnowMolecular Cardiovascular Research, Max-Delbrueck-Center for Molecular Medicine, 13092 Berlin, Germany.
Paul T PflugerResearch Unit Neurobiology of Diabetes, Helmholtz Zentrum München and Technical University Munich, 85764 Neuherberg, Germany.
Ruben NogueirasCIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-9976-9930
Vincent PrevotLille Neuroscience & Cognition, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Inserm, CHU Lille, University Lille, UMR-S1172, EGID, DISTALZ, F-59000 Lille, France.ORCID 0000-0001-7185-3615
Thomas KreyInstitute of Biochemistry, Center of Structural and Cell Biology in Medicine, University of Lübeck, 23562 Lübeck, Germany.ORCID 0000-0002-4548-7241
Markus SchwaningerInstitute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lübeck, 23562 Lübeck, Germany.ORCID 0000-0002-4510-9718
University of Lübeck · DEHelmholtz Zentrum München · DEInserm · FRJohannes Gutenberg University Mainz · DEMax Delbrück Center · DEMedizinische Hochschule Hannover · DEUniversidade de Santiago de Compostela · ES

Funding

DFG GRK1957H2020 European Research Council Grant-2019-WATCH-810331
6 · The paper itself

Abstract

The mechanisms underlying the transport of leptin into the brain are still largely unclear. While the leptin receptor has been implicated in the transport process, recent evidence has suggested an additional role of LRP2 (megalin). To evaluate the function of LRP2 for leptin transport across the blood-brain barrier (BBB), we developed a novel leptin-luciferase fusion protein (pLG), which stimulated leptin signaling and was transported in an in vitro BBB model based on porcine endothelial cells. The LRP inhibitor RAP did not affect leptin transport, arguing against a role of LRP2. In line with this, the selective deletion of LRP2 in brain endothelial cells and epithelial cells of the choroid plexus did not influence bodyweight, body composition, food intake, or energy expenditure of mice. These findings suggest that LRP2 at the BBB is not involved in the transport of leptin into the brain, nor in the development of obesity as has previously been described.

Indexed as

AnimalsBinding SitesBlood-Brain BarrierBody CompositionBody WeightCHO CellsChoroid PlexusCricetulusEndothelial CellsExtracellular Signal-Regulated MAP KinasesFemaleLeptinLow Density Lipoprotein Receptor-Related Protein-2LuciferasesMaleModels, BiologicalExtracellular Signal-Regulated MAP KinasesLeptinLow Density Lipoprotein Receptor-Related Protein-2Lrp2 protein, mouseLuciferasesReceptors, LeptinRecombinant Fusion Proteinsblood-brain barrierERK1/2fusion proteingaussia luciferaseleptinLRP2

Identifiers

PMID34066779
PMCPMC8125945
OpenAlexW3161328356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.